{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:51:14Z","timestamp":1794048674369,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was co-funded by the European &amp; Developing Countries Clinical Trials Partnership, The Hague, The Netherlands and Medicines for Malaria Venture, Geneva, Switzerland.","id":[{"id":"https:\/\/ror.org\/00p9jf779","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Several antimalarial drugs are known to prolong ventricular repolarization as evidenced by QT\/QTc interval prolongation. This can lead to Torsades de Pointes, a potentially lethal ventricular arrhythmia. Whether this is the case with artemisinin-based combination therapies (ACTs) remains uncertain. Assessment of the extent of QTc prolongation with antimalarials is hampered by important variations of heart rate during malaria crises and previous studies have reported highly variable values of QTc prolongations with ACTs. We assessed QTc prolongation with four ACTs, using high quality ECG recording and measurement techniques, during the first episode of malaria in 2,091 African patients enrolled in the WANECAM study which also monitored clinical safety. Using an original and robust method of QTc assessment, independent from heart rate changes and from the method of QT correction, we were able to accurately assess the extent of mean maximum QTc prolongation with the four ACTs tested. There was no evidence of proarrhythmia with any treatment during the study although dihydroartemisinin-piperaquine, artesunate-amodiaquine and artemether-lumefantrine significantly prolonged QTc. The extent of prolongation of ventricular repolarization can be accurately assessed in studies where heart rate changes impede QTc assessment.<\/jats:p>","DOI":"10.1038\/s41598-018-37113-5","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T06:03:17Z","timestamp":1548741797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0406-5189","authenticated-orcid":false,"given":"Christian","family":"Funck-Brentano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouhoum","family":"Ouologuem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Duparc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Felices","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sodiomon B.","family":"Sirima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issaka","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issiaka","family":"Soulama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Bosco","family":"Ouedraogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoul H.","family":"Beavogui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Borghini-Fuhrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulaye A.","family":"Djimd\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Voiriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,29]]},"reference":[{"key":"37113_CR1","unstructured":"WHO. World Malaria Report 2017, http:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2017\/en\/ (accessed 24 November May 2018)."},{"key":"37113_CR2","unstructured":"WHO. Guidelines for the treatment of malaria. Third edition, http:\/\/www.who.int\/malaria\/publications\/atoz\/9789241549127\/en\/ (accessed 24 November 2018)."},{"key":"37113_CR3","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.4269\/ajtmh.12-0290","volume":"88","author":"P Charle","year":"2013","unstructured":"Charle, P. et al. Artesunate\/amodiaquine malaria treatment for Equatorial Guinea (Central Africa). Am J Trop Med Hyg 88, 1087\u201392 (2013).","journal-title":"Am J Trop Med Hyg"},{"key":"37113_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-8-5","volume":"8","author":"K Kayentao","year":"2009","unstructured":"Kayentao, K. et al. Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali. Malar J 8, 5 (2009).","journal-title":"Malar J"},{"key":"37113_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-8-125","volume":"8","author":"JL Ndiaye","year":"2009","unstructured":"Ndiaye, J. L. et al. Randomized, multicentre assessment of the efficacy and safety of ASAQ\u2013a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar J 8, 125 (2009).","journal-title":"Malar J"},{"key":"37113_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0843-8","volume":"14","author":"P Sondo","year":"2015","unstructured":"Sondo, P. et al. Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial. Malar J 14, 325 (2015).","journal-title":"Malar J"},{"key":"37113_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4269\/ajtmh.2012.12-0025","volume":"87","author":"RM Fairhurst","year":"2012","unstructured":"Fairhurst, R. M. et al. Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am J Trop Med Hyg 87, 231\u201341 (2012).","journal-title":"Am J Trop Med Hyg"},{"key":"37113_CR8","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/S0140-6736(09)61856-0","volume":"374","author":"S Yeung","year":"2009","unstructured":"Yeung, S., Socheat, D., Moorthy, V. S. & Mills, A. J. Artemisinin resistance on the Thai-Cambodian border. Lancet 374, 1418\u20139 (2009).","journal-title":"Lancet"},{"key":"37113_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/inthealth\/ihv017","volume":"7","author":"E Pelfrene","year":"2015","unstructured":"Pelfrene, E., Pinheiro, M. H. & Cavaleri, M. Artemisinin-based combination therapy in the treatment of uncomplicated malaria: review of recent regulatory experience at the European Medicines Agency. Int Health 7, 239\u201346 (2015).","journal-title":"Int Health"},{"key":"37113_CR10","doi-asserted-by":"publisher","first-page":"17B","DOI":"10.1016\/0002-9149(93)90035-B","volume":"72","author":"C Funck-Brentano","year":"1993","unstructured":"Funck-Brentano, C. & Jaillon, P. Rate-corrected QT interval: techniques and limitations. Am. J. Cardiol. 72, 17B\u201322B (1993).","journal-title":"Am. J. Cardiol."},{"key":"37113_CR11","unstructured":"Eurartesim summary of product characteristics, https:\/\/www.ema.europa.eu\/documents\/product-information\/eurartesim-epar-product-information_en.pdf (accessed 24 November 2018)."},{"key":"37113_CR12","unstructured":"European Medicines Agency. Eurartesim assessment report - EMA\/739355\/2011, https:\/\/www.ema.europa.eu\/documents\/assessment-report\/eurartesim-epar-public-assessment-report_en.pdf (accessed 24 November 2018)."},{"key":"37113_CR13","doi-asserted-by":"publisher","first-page":"7340","DOI":"10.1128\/AAC.03704-14","volume":"58","author":"B Hanboonkunupakarn","year":"2014","unstructured":"Hanboonkunupakarn, B. et al. Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Antimicrob Agents Chemother 58, 7340\u20136 (2014).","journal-title":"Antimicrob Agents Chemother"},{"key":"37113_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.4269\/ajtmh.2007.77.447","volume":"77","author":"OT Mytton","year":"2007","unstructured":"Mytton, O. T. et al. Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. Am J Trop Med Hyg 77, 447\u201350 (2007).","journal-title":"Am J Trop Med Hyg"},{"key":"37113_CR15","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S0140-6736(18)30291-5","volume":"391","author":"West African Network for Clinical Trials of Antimalarial Drugs","year":"2018","unstructured":"West African Network for Clinical Trials of Antimalarial Drugs. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial. Lancet 391, 1378\u201390 (2018).","journal-title":"Lancet"},{"key":"37113_CR16","doi-asserted-by":"publisher","first-page":"6056","DOI":"10.1128\/AAC.02667-14","volume":"58","author":"J Manning","year":"2014","unstructured":"Manning, J. et al. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Antimicrob Agents Chemother 58, 6056\u201367 (2014).","journal-title":"Antimicrob Agents Chemother"},{"key":"37113_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1473-3099(07)70187-1","volume":"7","author":"NJ White","year":"2007","unstructured":"White, N. J. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 7, 549\u201358 (2007).","journal-title":"Lancet Infect Dis"},{"key":"37113_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/bcp.12680","volume":"80","author":"B Darpo","year":"2015","unstructured":"Darpo, B. et al. Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria. Br. J. Clin. Pharmacol. 80, 706\u201315 (2015).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"37113_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-420","volume":"11","author":"GO Adjei","year":"2012","unstructured":"Adjei, G. O. et al. Electrocardiographic study in Ghanaian children with uncomplicated malaria, treated with artesunate-amodiaquine or artemether-lumefantrine. Malar J 11, 420 (2012).","journal-title":"Malar J"},{"key":"37113_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-7-246","volume":"7","author":"CO Falade","year":"2008","unstructured":"Falade, C. O. et al. Evaluation of the efficacy and safety of artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in Nigerian infants and children. Malar J 7, 246 (2008).","journal-title":"Malar J"},{"key":"37113_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-70","volume":"12","author":"S Duparc","year":"2013","unstructured":"Duparc, S. et al. Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. Malar J 12, 70 (2013).","journal-title":"Malar J"},{"key":"37113_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1128\/AAC.03829-14","volume":"59","author":"P Jittamala","year":"2015","unstructured":"Jittamala, P. et al. Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Antimicrob Agents Chemother 59, 505\u201313 (2015).","journal-title":"Antimicrob Agents Chemother"},{"key":"37113_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4269\/ajtmh.2012.11-0558","volume":"86","author":"CA Morris","year":"2012","unstructured":"Morris, C. A. et al. Drug-drug interaction analysis of pyronaridine\/artesunate and ritonavir in healthy volunteers. Am J Trop Med Hyg 86, 489\u201395 (2012).","journal-title":"Am J Trop Med Hyg"},{"key":"37113_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1046\/j.1540-8167.2005.03520.x","volume":"16","author":"JF Wernicke","year":"2005","unstructured":"Wernicke, J. F., Faries, D., Breitung, R. & Girod, D. QT correction methods in children and adolescents. J Cardiovasc Electrophysiol 16, 76\u201381 (2005).","journal-title":"J Cardiovasc Electrophysiol"},{"key":"37113_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-219","volume":"13","author":"L Roggelin","year":"2014","unstructured":"Roggelin, L. et al. Disease-associated QT-shortage versus quinine associated QT-prolongation: age dependent ECG-effects in Ghanaian children with severe malaria. Malar J 13, 219 (2014).","journal-title":"Malar J"},{"key":"37113_CR26","doi-asserted-by":"publisher","first-page":"7321","DOI":"10.1128\/AAC.01748-15","volume":"60","author":"JA Green","year":"2016","unstructured":"Green, J. A. et al. Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects. Antimicrob Agents Chemother 60, 7321\u201332 (2016).","journal-title":"Antimicrob Agents Chemother"},{"key":"37113_CR27","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00228-009-0656-1","volume":"65","author":"V Navaratnam","year":"2009","unstructured":"Navaratnam, V. et al. Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers. Eur J Clin Pharmacol 65, 809\u201321 (2009).","journal-title":"Eur J Clin Pharmacol"},{"key":"37113_CR28","doi-asserted-by":"publisher","unstructured":"Funck-Brentano, C. et al. Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation. Sci. Rep., https:\/\/doi.org\/10.1038\/s41598-018-37112-6.","DOI":"10.1038\/s41598-018-37112-6"},{"issue":"960-4","key":"37113_CR29","first-page":"e1","volume":"166","author":"DQ Phan","year":"2015","unstructured":"Phan, D. Q., Silka, M. J., Lan, Y. T. & Chang, R. K. Comparison of formulas for calculation of the corrected QT interval in infants and young children. J Pediatr 166(960-4), e1\u20132 (2015).","journal-title":"J Pediatr"},{"key":"37113_CR30","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S1473-3099(18)30297-4","volume":"18","author":"XHS Chan","year":"2018","unstructured":"Chan, X. H. S. et al. Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis. Lancet Infect Dis 18, 913\u201323 (2018).","journal-title":"Lancet Infect Dis"},{"key":"37113_CR31","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S1473-3099(18)30360-8","volume":"18","author":"P Millat-Martinez","year":"2018","unstructured":"Millat-Martinez, P. & Bassat, Q. Reappraising the cardiosafety of dihydroartemisinin-piperaquine. Lancet Infect Dis 18, 824\u20136 (2018).","journal-title":"Lancet Infect Dis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37113-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37113-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37113-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:23:07Z","timestamp":1671236587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37113-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["37113"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-37113-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,29]]},"assertion":[{"value":"17 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was co-funded by the European & Developing Countries Clinical Trials Partnership, The Hague, The Netherlands and Medicines for Malaria Venture, Geneva, Switzerland. C.F.-B. received fees as a safety consultant on several antimalarial drugs developed by MMV. S.D. and I.B.-F. are full time employees at Medicines for Malaria Venture. M.F. received grants from Banook group\/Cardiabase, during the conduct of the study. Y.K. and P.V. received grants from MMV during the conduct of the study. Other authors have declared no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"883"}}